Disclosures: Jesse Pustjens: Nothing to Disclose, Laurens van Kleef: Nothing to Disclose, Harry Janssen: Gilead Sciences: and consultant, Gilead Sciences: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Janssen: Grant/Research Support, Roche: Grant/Research Support, Vir Biotechnology Inc.: Grant/Research Support, Aligos: Consultant, Gilead Sciences: Consultant, GlaxoSmithKline: Consultant, Grifols: Consultant, Roche: Consultant, Vir Biotechnology Inc: Consultant, Precision Biosciences: Consultant, Willem Pieter Brouwer: Nothing to Disclose 1121 INCREASING LIVER FIBROSIS IN MASLD IS ASSOCIATED WITH HIGHER RISK OF HIP FRACTURES IN MALES Elena Gibson 1 Meagan Gray 1 Fernando Bril 1 , 1 University of Alabama at Birmingham Background: Cirrhosis is associated with osteoporosis and increased risk of fractures

Abstract Background The systematic review aimed to assess the effects of GLP-1 receptor agonists (GLP-1 RA) and dual GLP-1/GIP agonists on weight loss and body composition in individuals with overweight or obesity, with or without type 2 diabetes mellitus
"People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm"
Interaction between phenolics and gut microbiota: role in human health